Multiple Myeloma Drugs Market Growth Forecast Through 2030: Market Size And Trends In 2026
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Multiple Myeloma Drugs Market CAGR Outlook And Future Development
The multiple myeloma drugs market size has experienced strong growth in recent years. It will grow from $23.03 billion in 2025 to $24.4 billion in 2026 at a compound annual growth rate (CAGR) of 6.0%. The growth observed in the past can be attributed to an increasing prevalence of multiple myeloma, the approval of novel immunomodulatory drugs, rising awareness concerning plasma cell cancers, the development of proteasome inhibitors, and the expansion of hospital pharmacy networks.
The multiple myeloma drugs market size is projected to experience robust growth in the upcoming years. It is forecast to expand to $31.61 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%. This anticipated growth during the forecast period is attributable to an increase in precision medicine adoption, rising investment in biologic therapies, an expanding geriatric population, the growth of online pharmacy distribution, and advancements in monoclonal antibody treatments. Significant trends during this period are expected to encompass the development of personalized therapies, the implementation of combination drug regimens, enhanced bone health management for multiple myeloma, the introduction of targeted drug delivery systems, and the expansion of clinical trials.
Get A Free Sample Report With In-Depth Market Insights:
Multiple Myeloma Drugs Market Demand Drivers: What’s Powering Industry Growth?
The rising occurrence of hematological cancer is projected to propel the expansion of the multiple myeloma drugs market in the coming years. These cancers originate in blood-forming tissues, like bone marrow, or in immune system cells, encompassing conditions such as leukemia, lymphoma, and multiple myeloma, among others. Medications for multiple myeloma are frequently administered to address various forms of the disease by eliminating and curbing the multiplication of cancer cells, achieved through slowing cell division via multiple enzymatic pathways, along with strengthening bones and alleviating discomfort in weakened bones. As an illustration, in January 2023, data from the American Cancer Society (ACS), a US-based health organization dedicated to eradicating cancer, indicated approximately 59,610 new diagnoses of leukemia and roughly 20,380 instances of acute myeloid leukemia (AML). Furthermore, the total fatalities linked to leukemia reached 23,710. Consequently, the growing prevalence of hematological cancer is fueling the growth of the multiple myeloma drugs market.
Multiple Myeloma Drugs Market Breakdown By Product Type And Application
The multiple myeloma drugs market covered in this report is segmented –
1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types
2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Men, Women
Subsegments:
1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide
2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib
3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin
4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab
5) By Steroids: Dexamethasone, Prednisone
6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs
Multiple Myeloma Drugs Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies in the multiple myeloma drug market are enhancing their partnership approaches to jointly create cell therapies, extending their collaborations to hasten the development and market introduction of next-generation CAR T products. Such strategic alliances facilitate combined resource utilization, risk reduction, and quicker scaling for new therapeutic options. As an example, in May 2024, Kite Pharma, a US-based biopharmaceutical company, and Arcellx, Inc., a US-based clinical-stage biotechnology company, announced important operational updates for their partnered BCMA CAR T therapy, anitocabtagene autoleucel (anito cel). The companies revealed the structure of a global Phase 3 trial, named iMMagine 3, which will assess anito cel in patients with relapsed or refractory multiple myeloma who have previously received both an immunomodulatory drug (IMiD) and an anti-CD38 monoclonal antibody. This trial is expected to recruit around 450 patients worldwide.
Multiple Myeloma Drugs Market Company Landscape And Competitive Strategy
Major companies operating in the multiple myeloma drugs market are Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Onyx Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., PharmaMar SA
View The Full Multiple Myeloma Drugs Market Report:
Multiple Myeloma Drugs Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the multiple myeloma drugs market in 2025. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
